智通财经APP讯,康方生物-B(09926)发布公告,公司与中国生物制药(01177)共同开发的抗PD-1单抗药物派安普利(安尼可)联合紫杉醇和卡铂用于局部晚期或转移性鳞状非小细胞肺癌一线治疗的III期临床试验中期分析,达到主要研究终点。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.